RESUMO
The results of assay of receptorial status of tumor in 152 primary patients with endometrial carcinoma are presented. It was shown that a 10-day course of preoperative Tamoxifen therapy (course dose 0.6 g) was able to increase significantly concentrations of nuclear estradiol receptors and cytoplasmatic progesterone receptors in the tumor. This phenomenon followed morphological changes in the tumor and was established in both hormone dependent type (72.7%) and hormone independent type of endometrial carcinoma (45.5%). The assay of the dynamics of receptorial status of primary endometrial carcinoma under influence of Tamoxifen before surgery might be an informative test for selection of sensitive patients with poor prognosis for prolonged hormone therapy in remission to prevent development of recurrencies.
Assuntos
Neoplasias do Endométrio/tratamento farmacológico , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Receptores de Estradiol/biossíntese , Receptores de Progesterona/biossíntese , Tamoxifeno/uso terapêutico , Núcleo Celular/metabolismo , Citoplasma/metabolismo , Neoplasias do Endométrio/complicações , Neoplasias do Endométrio/metabolismo , Feminino , Humanos , Hiperlipidemias/complicações , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , Neoplasias Hormônio-Dependentes/complicações , Neoplasias Hormônio-Dependentes/metabolismo , Obesidade/complicações , Obesidade/metabolismoRESUMO
The paper presents the results of treatment of 488 patients with primary endometrial carcinoma. All patients received adjuvant hormonotherapy (oxyprogesterone caproate, and some patients previously oestrogens) in combination with surgery and postoperative irradiation. The study of tumor morphology on ultrastructural level and by histochemical methods provided additionally useful findings. Depending on the degree of changes in the tumor structure after hormone therapy it appeared possible to distinguish the following varieties of results: 1) Complete regression of tumor. 2) An increase in structural and functional differentiation as compared with the initial level differentiation of tumor. 3) Absence or doubtful effect. In the paper the working classification of malignant adrenogenic tumors of the uterus is presented.
Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Neoplasias do Endométrio/tratamento farmacológico , Hidroxiprogesteronas/uso terapêutico , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Caproato de 17 alfa-Hidroxiprogesterona , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Adulto , Antineoplásicos/farmacologia , Divisão Celular/efeitos dos fármacos , Quimioterapia Adjuvante , Clomifeno/uso terapêutico , Anticoncepcionais Orais Hormonais/uso terapêutico , Neoplasias do Endométrio/metabolismo , Neoplasias do Endométrio/patologia , Neoplasias do Endométrio/cirurgia , Enzimas/biossíntese , Estradiol/análogos & derivados , Estradiol/farmacologia , Estradiol/uso terapêutico , Feminino , Glicogênio/biossíntese , Humanos , Hidroxiprogesteronas/farmacologia , Microscopia Eletrônica , Estadiamento de Neoplasias , Neoplasias Hormônio-Dependentes/metabolismo , Neoplasias Hormônio-Dependentes/patologia , Neoplasias Hormônio-Dependentes/cirurgia , Indução de RemissãoRESUMO
The results of preoperative use of oxyprogesterone caproate (OPC), Tamoxifen and their combination in 165 patients suffering from primary endometrial carcinoma are presented. It was shown that Tamoxifen was able to increase concentrations cytoplasmatic receptors to progesterone in the tumor. The incidence of specific hormonal pathomorphosis in the tissue of the tumor in patients who received a combination of OPC and Tamoxifen was significantly higher (80% of cases) as compared to the separate use of OPC (60%) or Tamoxifen (57%).
Assuntos
Hidroxiprogesteronas/uso terapêutico , Receptores de Estradiol/metabolismo , Receptores de Progesterona/metabolismo , Tamoxifeno/uso terapêutico , Neoplasias Uterinas/metabolismo , Caproato de 17 alfa-Hidroxiprogesterona , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Citoplasma/metabolismo , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/metabolismo , Humanos , Hidroxiprogesteronas/administração & dosagem , Hormônio Luteinizante/metabolismo , Pessoa de Meia-Idade , Tamoxifeno/administração & dosagem , Neoplasias Uterinas/tratamento farmacológico , Neoplasias Uterinas/patologia , Vagina/patologiaRESUMO
The data on 19 cases of primary endometrial carcinoma, stage I (mean age 28.0 years), cured by the administration of hydroxyprogesterone caproate without surgery and radiation therapy are presented. Clinical recovery in 15 cases was confirmed by repeated cytological and histological examinations of the endometrium. Hydroxyprogesterone caproate dose per course ranged within 25.0-83.0 g. In 4 patients with moderately differentiated cancer (G2), hormonal treatment was carried out in combination with chemotherapy. When tumor regression was confirmed histologically, steroid contraceptives were administered to induce an artificial menstrual cycle. At the closing stage of therapy clomiphene citrates were given in succession to restore the ovulatory cycle. Perspectives of administration of progestogens in young women with stage I endometrial carcinoma as a separate method of therapy are discussed.